Ozempic Wars | The Hundred-Year Duel | 1

What It Covers

Novo Nordisk's development of Ozempic and Wegovy transforms diabetes treatment into a $28 billion weight loss industry, triggering supply shortages, counterfeit drug proliferation, and intensified competition with century-old rival Eli Lilly.

Key Questions Answered

• •Product Innovation Through Empathy: Novo Nordisk reduced GLP-1 injections from twice daily to once weekly by extending semaglutide's half-life, demonstrating how removing customer friction unlocks exponential demand beyond what advertising alone can achieve in pharmaceutical markets.
• •Marketing in Regulatory Gray Zones: Novo Nordisk advertised Ozempic with weight loss messaging while displaying "not a weight loss drug" disclaimers, showing how companies hint at benefits without explicit claims, making what audiences hear more powerful than literal statements.
• •Supply Shortage Creates Competition: When Wegovy shortages triggered FDA shortage listings in March 2022, federal law allowed compounding pharmacies to produce copycat versions despite patents, demonstrating how inability to meet demand creates shadow markets that erode brand control and reputation.
• •Dual-Front Market Defense: Novo Nordisk invested $700 million in production facilities while facing both legitimate competitor Eli Lilly's Monjaro launch and thousands of unregulated counterfeit semaglutide vials, requiring simultaneous capacity expansion and quality control enforcement to maintain market position.